Lei Jianping on January 11
Suzhou Saifen Technology Co., Ltd. *** referred to as "Saifen Technology") recently passed the IPO meeting and is preparing to be listed on the Science and Technology Innovation Board. Saifen Technology plans to raise 800 million yuan.
Of these, 33.4 billion yuan for 200,000 liters of excipients for biomedical separation and purification, 19.5 billion yuan for the construction project of the R&D center, 2700 million yuan to replenish liquidity.
Annual revenue of 2100 million
SepaxxTechnologies, IncFounded in 2002 in Delaware, USA, it is committed to the development and production of liquid chromatography materials and technologies for the separation and purification of drugs such as biological macromolecules.
After 20 years of deep cultivation in the field of chromatography chromatography, Saifen Technology has developed into an enterprise integrating R&D, production and global sales, the company's main products are chromatography chromatography media and liquid chromatography columns, providing global biopharmaceutical companies with full-cycle analysis chromatography and industrial purification solutions from drug research and development, pre-clinical (pre-IND) to clinical, period, production and quality control.
In 2009, Saifen Technology implemented China's development strategy and established Suzhou Saifen Technology Co., Ltd. to settle down and take root in Suzhou Industrial Park. In February 2018, the 26,000-square-meter headquarters building was completed.
According to the prospectus, Saifen Technology's revenue in 2020, 2021, and 2022 will be 97.67 million yuan and 15.5 billion yuan, 2$1.3 billion; The net profit was 938570,000 yuan, 21.62 million yuan, 48.2 million yuan; The net profit after deducting non-profits was 64680,000 yuan, 200170,000 yuan, 41.09 million yuan.
Saifen Technology's revenue in the first half of 2023 will be 13.4 billion yuan, net profit of 31.94 million yuan, net profit after deducting non-profit of 27.11 million yuan.
Yuanfeng Pansai and Hillhouse Qirui are shareholders
Before the IPO, Huang Xueying directly held 92,364,177 shares of the company, accounting for 25 of the company's total share capital2%, which is the controlling shareholder of the company. At the same time, Huang Xueying is the general partner of Suzhou Xianda and Suzhou Jiexian, and Suzhou Xianda and Suzhou Jiexian respectively hold 421% and 218%。
Therefore, Huang Xueying controls a total of 31 shares in the company59%, which is the actual controller of the company.
Zhou Jinqing, born in 1941, directly owns the company 879% of the shares. Lu Min, male, born in 1964, Chinese nationality, permanent residency in the United States, Lu Min directly holds the company 808% equity. Lu Min is currently the general manager of Shenzhen Mopai Technology.
Weizheng Xu indirectly controls the company through Suzhou Boda and Haijia Tongkang361% and 149% of the shares, a total of 509% equity. Weizheng Xu, born in 1964, is an American citizen.
Before the IPO, Gaoxin Tonghua held 84723%, 78467%, Huatai Health No. 1 holds 54972%, Yuanfeng Pansai holds 49322%, Suzhou Xianda holds 42095%, Fosun Weiying's shareholding is 39651%, Suzhou Boda holds 36067%, Suzhou Jiexian holds 21802%；
Pan Ding's shareholding is 19831%, Zhuhai Luanheng and Hillhouse Qirui hold 19729%, Haijia Tongkang holds 14874%, Sinopharm Zhongsheng holds 14492%, Suzhou Dunxing holds 12552%, Sherpa II holds 1233%, Chen Zhihua holds 09426%, Geng Weidong holds 09414%；
Gan & Lee Pharmaceutical's shareholding is 07398%, Junyao Investment holds 06276%, Zhu Qinhua holds 0609%, Wu Zhengtao holds 04932%, Sinopharm Phase II holds 04883%, Huatai Health No. 2 holds 03767%, Jubei Investment holds 03699%。
After the IPO, Huang Xueying's direct shareholding was 226822%, Zhou Jinqing holds 79075%, and the shareholding of high-tech Tonghua is 76251%, and Lu Min holds 72692%, and the shareholding of Guoshou Qiquan is 7062%, Huatai Health No. 1 holds 49475%, Yuanfeng Pansai holds 4439%；
Suzhou Xianda holds 37885%, Fosun Weiying holds 35686%, Suzhou Boda holds 3246%, Suzhou Jiexian holds 19622%, Pan Ding holds 17848%, Zhuhai Luanheng and Hillhouse Qirui respectively hold 17756%, Haijia Tongkang holds 13386%, Sinopharm Zhongsheng holds 13043%, Suzhou Dunxing holds 11296%；
Sherpa II holds 11097%, Chen Zhihua holds 08484%, Geng Weidong holds 08472%, Gan & Lee Pharmaceutical holds 06658%, Junyao Investment holds 05648%, Zhu Qinhua holds 05481%, Wu Zhengtao's shareholding is 04439%, Sinopharm Phase II holds 04395%, Huatai Health No. 2 holds 0339%, Jubei Investment holds 03329%。
Lei Di was founded by ** Lei Jianping, if ** please in**.